A naukri.com initiative
Bioengineer
2d
3
Image Credit: Bioengineer
Dual-Targeted CAR T Cell Therapy Shows Promise in Slowing Aggressive Brain Tumor Progression
- Researchers at the University of Pennsylvania have developed a dual-target CAR T cell therapy for recurrent glioblastoma, a highly aggressive brain tumor.
- The therapy targets two tumor proteins, EGFR and IL13Rα2, and has shown promising results in shrinking tumors and improving survival rates.
- The approach involves genetically engineering the patient's immune cells to enhance their ability to recognize and attack the tumor.
- Preliminary data from the clinical trial demonstrate significant tumor reduction in 62% of patients with measurable tumors post-surgery.
- The therapy has shown durable effects, with some patients maintaining active CAR T cells for over a year.
- The study challenges the notion that the brain's immune-privileged status hinders immunotherapy efficacy by delivering the treatment via cerebrospinal fluid.
- Safety concerns were addressed, with manageable neurotoxicity observed in over half of the patients at grade 3 severity.
- Outcomes from the trial suggest a potential shift in GBM treatment paradigms, with some patients surpassing the one-year survival mark.
- Future research aims to optimize therapeutic efficacy through repeat dosing strategies and expand the application of multi-antigen targeting in other solid tumors.
- This groundbreaking work combines gene editing, neuro-oncology, and immunotherapy to pave the way for novel strategies in cancer treatment.
Read Full Article
Like
For uninterrupted reading, download the app